Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | OGG1 | O15527 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30758864 | 0.88 | PARP1 (0.61) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL8071350 | 0.86 | KMT2A (0.50) | L3MBTL1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4453392 | 0.85 | L3MBTL1 (0.56) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1814265 | 0.84 | SMN1; SMN2 (0.56) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL5873149 | 0.83 | MEN1 (0.65) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1162756 | 0.83 | PARP1 (0.55) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2203444 | 0.82 | PARP1 (0.59) | L3MBTL1PARP1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL13918097 | 0.82 | L3MBTL1 (0.53) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1808868 | 0.81 | PARP1 (0.62) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL31149717 | 0.81 | PARP1 (0.62) | L3MBTL1PARP1ALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103936631-B | A kind of Biphenyl carbamide compound containing oximido and its preparation method and application | XI'AN JIAOTONG UNIVERSITY (CN) | 2015-08-05 | — | — | CN | claimed |
| CN-110204487-B | Synthesis method of quinoline derivative | 江南大学 | 2021-09-28 | — | — | CN | disclosed |
| CN-103936631-B | A kind of Biphenyl carbamide compound containing oximido and its preparation method and application | XI'AN JIAOTONG UNIVERSITY (CN) | 2015-08-05 | — | — | CN | disclosed |
| EP-2394998-A1 | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| EP-2394998-A1 | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-7105518-B2 | Thiopyrane-4-ones as DNA protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1416936-B1 | THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS | CANCER REC TECH LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20050107367-A1 | Thiopyrane-4-ones as dna protein kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1416936-A1 | THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015790-A1 | THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107367-A1 | Thiopyrane-4-ones as dna protein kinase inhibitors | DTYMK, DCK, TK1 | L3MBTL1 825/4885PARP1 265/4885ALDH1A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.